A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma.

BACKGROUND We conducted a prospective randomized controlled trial comparing surgery alone (S) with concurrent chemoradiotherapy followed by surgery (CRT-S) for resectable esophageal squamous cell carcinoma (SCC) based on our previous report. PATIENTS AND METHODS One hundred and one patients with stage II/III esophageal SCC were randomized to receive either S (50 patients) or CRT-S (51 patients). The chemoradiotherapy (CRT) consisted of cisplatin 60 mg/m(2) intravenously (i.v.) on day 1, 5-fluorouracil (5-FU) 1000 mg/m(2) i.v. on days 2-5, cisplatin 60 mg/m(2) i.v. on day 22 combined with radiation therapy (45.6 Gy, 1.2 Gy b.i.d. on days 1-28). Surgery was performed 3-4 weeks after radiotherapy was completed. For patients with disease that was stable or responsive to CRT, three additional cycles of chemotherapy (cisplatin 60 mg/m(2) i.v. on day 1, 5-FU 1000 mg/m(2) on days 2-5 every 4 weeks) were given after surgical resection. RESULTS The median age was 62 years. The toxicity of CRT was acceptable and did not affect the post-operative morbidity and the duration of hospital stay. Clinical response was 86% including 21% of complete response (CR) rate. Pathological CR was achieved in 43% [95% confidence interval (CI) 27-59] of the patients who underwent surgery after CRT. At a median follow-up of 25 months, median overall survival (OS) was 27.3 months in S and 28.2 months in CRT-S (P = 0.69). Event-free survival (EFS) at 2 years was 51% in S and 49% in CRT-S (P = 0.93). This trial, which was statistically powered to detect a relatively large difference in 2-year survival rate from 30% to 50% with 80% power, was discontinued at interim analysis because of the unexpectedly high drop-out rate for esophagectomy (31%) and resultant excessive locoregional failure rate in CRT-S arm (22% versus 12%, P = 0.31), though it was not statistically significant. CONCLUSION Although preoperative CRT induced high clinical and pathological response, there was no statistically significant benefit in OS and EFS.

[1]  R. Hatlevoll,et al.  Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: A randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second scandinavian trial in esophageal cancer , 1992, World Journal of Surgery.

[2]  H. Fujita,et al.  [Chemoradiotherapy for esophageal cancer]. , 2003, Gan to kagaku ryoho. Cancer & chemotherapy.

[3]  Sung-Bae Kim,et al.  Efficacy of Neoadjuvant Chemoradiotherapy in Resectable Esophageal Squamous Cell Carcinoma , 2003, Acta oncologica.

[4]  J. Urschel,et al.  A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. , 2002, American journal of surgery.

[5]  Paul Fockens,et al.  Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. , 2002, The New England journal of medicine.

[6]  P. Vos,et al.  Preoperative Chemotherapy and Radiation for Advanced Esophageal Carcinoma: Comparison Between Once a Day Radiation and Hyperfractionation, a Single-Institution Experience , 2002, American journal of clinical oncology.

[7]  D. Girling Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial , 2002, The Lancet.

[8]  V. Gebski,et al.  A randomized phase III trial of preoperative chemoradiation followed by surgery (CR-S) versus surgery alone (S) for localized resectable cancer of the esophagus , 2002 .

[9]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[10]  M. Iannettoni,et al.  Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Strander,et al.  A Swedish Study of Chemoradiation in Squamous Cell Carcinoma of the Esophagus , 2001, Acta oncologica.

[12]  M. Talamini,et al.  Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Ajani,et al.  Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. , 1998, The New England journal of medicine.

[14]  J. Geraghty,et al.  Oesophageal cancer treatment: studies, strategies and facts. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  D. Heresbach,et al.  Neoadjuvant chemotherapy and hyperfractionated radiotherapy with concurrent low-dose chemotherapy for squamous cell esophageal carcinoma. , 1998, International journal of radiation oncology, biology, physics.

[16]  B. Jeremic,et al.  Accelerated hyperfractionated radiation therapy and concurrent 5-fluorouracil/cisplatin chemotherapy for locoregional squamous cell carcinoma of the thoracic esophagus: a phase II study. , 1998, International journal of radiation oncology, biology, physics.

[17]  N. Choi,et al.  Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. , 1997, The Journal of thoracic and cardiovascular surgery.

[18]  T. Rice,et al.  Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma , 1997, Cancer.

[19]  P. Hoskin,et al.  Continuous hyperfractionated accelerated radiotherapy (CHART) in localized cancer of the esophagus. , 1997, International journal of radiation oncology, biology, physics.

[20]  J. Bosset,et al.  Chemotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus , 1998 .

[21]  T. Walsh,et al.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. , 1996, The New England journal of medicine.

[22]  H. Sack,et al.  Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. Detterbeck,et al.  Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Puttisak,et al.  A prospective study of combined therapy in esophageal cancer. , 1994, Hepato-gastroenterology.

[25]  M. Hassel,et al.  A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus , 1994, Cancer.

[26]  S. Hoff,et al.  Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma. , 1993, The Annals of thoracic surgery.

[27]  M. Orringer,et al.  Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Stelzner,et al.  Surgical therapy of oesophageal carcinoma , 1990, The British journal of surgery.

[29]  G. Fletcher,et al.  Accelerated fractionation vs hyperfractionation: rationales for several treatments per day. , 1983, International journal of radiation oncology, biology, physics.

[30]  L. Freedman Tables of the number of patients required in clinical trials using the logrank test. , 1982, Statistics in medicine.

[31]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[32]  N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[33]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .